[go: up one dir, main page]

NO974943L - Angiostatinfragmenter, aggregert angiostatin og anvendelse derav - Google Patents

Angiostatinfragmenter, aggregert angiostatin og anvendelse derav

Info

Publication number
NO974943L
NO974943L NO974943A NO974943A NO974943L NO 974943 L NO974943 L NO 974943L NO 974943 A NO974943 A NO 974943A NO 974943 A NO974943 A NO 974943A NO 974943 L NO974943 L NO 974943L
Authority
NO
Norway
Prior art keywords
angiostatin
fragments
proliferation inhibitor
aggregated
aggregate
Prior art date
Application number
NO974943A
Other languages
English (en)
Other versions
NO974943D0 (no
Inventor
Moses Judah Folkman
Michael S O'reilly
Yihai Cao
Jie Lin
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/429,743 external-priority patent/US5885795A/en
Priority claimed from US08/605,598 external-priority patent/US5861372A/en
Priority claimed from US08/612,788 external-priority patent/US5837682A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of NO974943D0 publication Critical patent/NO974943D0/no
Publication of NO974943L publication Critical patent/NO974943L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
NO974943A 1995-04-26 1997-10-24 Angiostatinfragmenter, aggregert angiostatin og anvendelse derav NO974943L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/429,743 US5885795A (en) 1994-04-26 1995-04-26 Methods of expressing angiostatic protein
US08/605,598 US5861372A (en) 1996-02-22 1996-02-22 Aggregate angiostatin and method of use
US08/612,788 US5837682A (en) 1996-03-08 1996-03-08 Angiostatin fragments and method of use
PCT/US1996/005856 WO1996035774A2 (en) 1995-04-26 1996-04-26 Angiostatin fragments and aggregate angiostatin and methods of use

Publications (2)

Publication Number Publication Date
NO974943D0 NO974943D0 (no) 1997-10-24
NO974943L true NO974943L (no) 1997-12-18

Family

ID=27411639

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974943A NO974943L (no) 1995-04-26 1997-10-24 Angiostatinfragmenter, aggregert angiostatin og anvendelse derav

Country Status (17)

Country Link
EP (1) EP0824546B1 (no)
JP (2) JP3787157B2 (no)
CN (1) CN1195375A (no)
AT (1) ATE368051T1 (no)
AU (1) AU709633B2 (no)
BR (1) BR9608326A (no)
CA (1) CA2219081C (no)
CZ (1) CZ334097A3 (no)
DE (1) DE69637179T2 (no)
ES (1) ES2292174T3 (no)
HK (1) HK1002457A1 (no)
HU (1) HUP9800784A3 (no)
MX (1) MX9708217A (no)
NO (1) NO974943L (no)
NZ (1) NZ307044A (no)
PL (1) PL323256A1 (no)
WO (1) WO1996035774A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
ATE262537T1 (de) * 1995-12-13 2004-04-15 Childrens Medical Center Proliferationsinhibitor von endothellzellen und dessen verwendung
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
CA2303401A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
AU1598599A (en) * 1997-11-20 1999-06-15 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
EP1037983A1 (en) * 1997-12-08 2000-09-27 Beth Israel Deaconess Medical Center Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CA2263784A1 (en) * 1998-03-23 1999-09-23 Megabios Corporation Dual-tagged proteins and their uses
DE69939586D1 (de) * 1998-04-28 2008-10-30 Toshikazu Nakamura Inhibitoren für die gefässneubildung
WO1999061464A1 (en) * 1998-05-28 1999-12-02 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
CA2335038A1 (en) 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2360690A1 (en) * 1999-01-28 2000-08-03 Michael S. O'reilly Plasminogen kringle 4 region fragments and methods of use
ATE360062T1 (de) * 1999-02-10 2007-05-15 Childrens Medical Center Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
US7157556B1 (en) 1999-02-10 2007-01-02 The Children's Medical Center Corporation Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
AR030631A1 (es) * 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
WO2003086178A2 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20070031379A1 (en) * 2004-01-09 2007-02-08 Lee Kyu H Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
WO2005079835A1 (ja) * 2004-02-24 2005-09-01 Ttc Co., Ltd. Ｂｌアンジオスタチンを含む制がん剤
ITMI20041962A1 (it) * 2004-10-15 2005-01-15 Istituto Naz Per La Ricerca S "peptide di angiostatina e suoi impieghio terapeutici"
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2010070746A1 (ja) * 2008-12-17 2010-06-24 株式会社ティムス イヌアンジオスタチン様ポリペプチド
JP5749229B2 (ja) * 2012-07-31 2015-07-15 京セラドキュメントソリューションズ株式会社 ジェスチャー管理プログラム及び情報処理装置
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
DK3556383T5 (da) 2016-12-15 2024-09-02 Talengen Int Ltd Plasminogen til anvendelse ved behandling af diabetes
AU2018326835A1 (en) * 2017-08-31 2020-03-26 National University Of Singapore Angio-3 for treatment of retinal angiogenic diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76095A (en) * 1994-04-26 1997-06-30 Childrens Medical Center Angiostatin and method of use for inhibition of angiogenesis

Also Published As

Publication number Publication date
WO1996035774A2 (en) 1996-11-14
CA2219081A1 (en) 1996-11-14
DE69637179T2 (de) 2008-04-10
CA2219081C (en) 2004-02-24
ES2292174T3 (es) 2008-03-01
AU709633B2 (en) 1999-09-02
NO974943D0 (no) 1997-10-24
BR9608326A (pt) 2000-03-08
JP3787157B2 (ja) 2006-06-21
PL323256A1 (en) 1998-03-16
AU5579596A (en) 1996-11-29
MX9708217A (es) 1997-12-31
CZ334097A3 (cs) 1998-04-15
EP0824546B1 (en) 2007-07-25
HK1002457A1 (en) 1998-08-28
NZ307044A (en) 2002-03-01
DE69637179D1 (de) 2007-09-06
HUP9800784A2 (hu) 1998-07-28
WO1996035774A3 (en) 1997-02-13
CN1195375A (zh) 1998-10-07
EP0824546A2 (en) 1998-02-25
ATE368051T1 (de) 2007-08-15
JP2001151691A (ja) 2001-06-05
HUP9800784A3 (en) 2000-07-28
JPH11508228A (ja) 1999-07-21

Similar Documents

Publication Publication Date Title
NO974943L (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
CA2291892A1 (en) Angiostatin fragments and method of use
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
MXPA00004256A (es) Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
ATE214075T1 (de) Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
EA199900162A1 (ru) Ингибиторы клеточной адгезии
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
AU2209800A (en) Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
AU7934900A (en) Method of screening for inhibitors of asp2
DE69620458D1 (de) Benzofuran-carboxamide und -sulfonamide
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
WO1999057133A3 (en) Inhibitors of nf-kb activation
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
IS1986B (is) Notkun CD137 til að stuðla að fjölgun jaðar-einkjörnunga
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
ATE239076T1 (de) Zielspezifische abgabe zum nukleus mittels protein h von streptococcus
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application